33 related articles for article (PubMed ID: 3611859)
1. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
2. Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR).
Penna GO; Pontes MAA; Talhari S; Gonçalves HS; Talhari C; Pessoa AS; Pedroza V; Bührer-Sékula S; Stefani MMA; Penna MLF
Braz J Infect Dis; 2024; 28(2):103745. PubMed ID: 38697216
[TBL] [Abstract][Full Text] [Related]
3. Adverse reactions induced by MDT/WHO (Rifampicin+Clofazimine+Dapsone) and ROM (Rifampicin+Ofloxacin+Minocycline) regimens used in the treatment of leprosy: a cohort study in a National Reference Center in Brazil.
Celestino IC; Antunes DE; Santos DF; Gimenes VL; de Souza FM; Goulart IMB
Front Pharmacol; 2024; 15():1346169. PubMed ID: 38515839
[No Abstract] [Full Text] [Related]
4. Acceptability of clofazimine capsules in children and adolescents with rifampicin-resistant TB.
Wademan DT; Saule Z; Marthinus A; Viljoen L; Nortier E; Hughes J; Courtney I; Palmer M; Garcia-Prats AJ; Hesseling AC; Hoddinott G
Int J Tuberc Lung Dis; 2024 May; 28(5):256-258. PubMed ID: 38659140
[No Abstract] [Full Text] [Related]
5. Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa ; Sharma VD; Shivannavar CT; Katoch VM
Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):451-7. PubMed ID: 2664042
[TBL] [Abstract][Full Text] [Related]
6. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
Katoch K; Natarajan M; Bagga A; Katoch VM
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
9. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
[TBL] [Abstract][Full Text] [Related]
10. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
[TBL] [Abstract][Full Text] [Related]
11. [Immuno-allergic accidents with rifamipcin].
Flageul B; Wagner L; Cottenot F
Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
[TBL] [Abstract][Full Text] [Related]
12. Leprosy. Recognition and treatment.
Ramos-e-Silva M; Rebello PF
Am J Clin Dermatol; 2001; 2(4):203-11. PubMed ID: 11705247
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
